NSE · CHANDAN · Healthcare
Chandan Healthcare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹49 Cr with net profit ₹7 Cr — a 13.79% net margin, versus 9.64% the period before.
Shareholding
As of 2026-09-30
- Promoter48.42%
- Public46.52%
- DII5.06%
1,688 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.93× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 1.19 percentage points to 48.42% in the latest disclosure.
Peer comparison
Healthcare · ranked #34 of 85 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,11,146 Cr | 52.83 | 11.73 | 20.48% | 7.91% |
| Manipal Health Enterpri Limited | ₹79,889 Cr | 85.18 | 4.86 | 10.59% | 7.81% |
| Max Healthcare Institute Ltd. | ₹79,325 Cr | 52.99 | 7.4 | 13.42% | 16.73% |
| Aster DM Quality Care Ltd. | ₹56,223 Cr | 144.94 | 13.37 | 8.48% | 6.54% |
| Fortis Healthcare Ltd. | ₹53,821 Cr | 50.45 | 5.49 | 10.53% | 11.02% |
| Narayana Hrudayalaya Ltd. | ₹33,656 Cr | 39.04 | 7.42 | 17.76% | 9% |
| Global Health Limited | ₹31,862 Cr | 55.66 | 8.04 | 14.05% | 11.88% |
| Dr. Lal Path Labs Ltd. | ₹30,854 Cr | 54.86 | 12.35 | 20.13% | 18.75% |
| Krishna Institute of Medical Sciences Ltd. | ₹27,937 Cr | 133.83 | 7.47 | 10.74% | 4.85% |
| Dr. Agarwal's Health Care Limited | ₹15,025 Cr | 101.91 | 7.44 | 6.58% | 6.72% |
| Chandan Healthcare Ltd.(this company) | ₹535 Cr | 20.35 | 3.15 | 11.34% | 8.55% |
AI analysis
AI-generated · google/gemini-2.5-flashChandan Healthcare Ltd. is listed with a market capitalization of Rs 593 Cr. The company reported revenue of Rs 232.17 Cr and a profit margin of 9.79%. Its price-to-earnings ratio stands at 85.74, with an EPS of 11.96. Return on equity is 15.82% and return on capital employed is 19.64%.
Positives
- +Revenue grew 30.3% to Rs 232.17 Cr.
- +Return on capital employed (ROCE) is 19.64%.
- +Debt-to-equity ratio at 0.51 is moderate.
- +No promoter shares are pledged.
Negatives
- −The price-to-earnings (P/E) ratio is 85.74 times its EPS of Rs 11.96.
- −Quarterly EPS figures are not disclosed since Dec 2024.
- −The dividend yield is 0%, indicating no dividends distributed.
- −Promoter holding decreased from 69.9291% in Sept 2024 to 49.5487% in Mar 2026.
Financial performance
For the last reported fiscal year, Chandan Healthcare Ltd. generated revenue of Rs 232.17 Cr. This represents a revenue growth of 30.3%. Net profit for the period was Rs 22.17 Cr, resulting in an EPS of Rs 11.96. The company's profit margin stood at 9.79%.
Profitability & returns
The company maintained a profit margin of 9.79%. Return on equity (ROE) for Chandan Healthcare Ltd. was 15.82%, while return on capital employed (ROCE) was 19.64%. The company's earnings per share (EPS) was Rs 11.96.
Balance sheet
Chandan Healthcare Ltd. has a debt-to-equity ratio of 0.51, indicating a moderate level of debt relative to its equity. The book value per share is Rs 69.48.
Ownership & pledges
As of March 31, 2026, promoter holding in Chandan Healthcare Ltd. was 49.54%. Public shareholders held 45.41% of the company, while institutional holdings, including DIIs and FIIs, accounted for 5.03%. There are no reported promoter pledges.
Regulatory & surveillance
The company is not currently listed under any surveillance measures.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.